A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling

Br J Haematol. 2011 Aug;154(4):529-33. doi: 10.1111/j.1365-2141.2011.08622.x. Epub 2011 Apr 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / adverse effects*
  • Case-Control Studies
  • Diphosphonates / adverse effects*
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Humans
  • Imidazoles / adverse effects*
  • Jaw Diseases / genetics
  • Middle Aged
  • Multiple Myeloma / genetics*
  • Osteonecrosis / genetics*
  • PPAR gamma / genetics*
  • Polymorphism, Single Nucleotide
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • PPAR gamma
  • Zoledronic Acid